At Helix Biogen Institute, we are at the forefront of innovative vaccine development, combining advanced bioinformatics, cutting-edge biotechnology, and scientific expertise to tackle global health challenges.

Our research is dedicated to designing highly effective and safe vaccines, particularly against emerging infectious diseases. Through a multidisciplinary approach, we leverage the latest breakthroughs in computational biology, immunoinformatics, and molecular engineering to create next‑generation vaccines.

● SARS‑CoV‑2 Vaccine (Candidate 1 & 2)

In a groundbreaking collaboration, Helix Biogen Institute and Thelvax are developing an innovative COVID‑19 vaccine candidate designed to combat SARS‑CoV‑2 effectively. Leveraging advanced protein expression technology, the antigenic components of the virus’s surface glycoprotein are produced using E. coli and insect cell systems, ensuring high-yield and cost-effective production while maintaining immunogenic integrity.

● Lassa Virus Vaccine (Candidates 1–3)

Lassa fever remains a significant public health threat in West Africa. Our candidate utilizes virus-like particles (VLPs) and adjuvants to present nucleoprotein and glycoprotein components for broad neutralizing responses. A second variant focusing on nucleoprotein-only epitopes is also in development.

● Hepatitis E Vaccine (HEV)

A novel vaccine candidate aimed at long-lasting protection against Hepatitis E is progressing toward animal trials, particularly targeting regions with waterborne transmission and limited sanitation.

● Nipah Virus Vaccine

Combining immunoinformatics and agent-based immune modeling, this vaccine candidate is undergoing in vitro and in vivo testing to predict and enhance T‑ and B‑cell responses.

● Mokola Virus Vaccine

Targeting this rare but neurologically severe virus, our design emphasizes early mitigation of emerging disease threats through proactive vaccine development partnerships.

● Rift Valley Fever Vaccine

Designed to protect ruminant livestock and reduce zoonotic transmission, this candidate aims to secure food systems and public health in vulnerable regions.

● Igbo Ora Virus Vaccine

Although cases are rare, the development of a vaccine for Igbo Ora virus aligns with our commitment to proactive defense against emerging pathogens.